专家视角:免疫检查点抑制剂与风湿病学并发症
本文综述了免疫检查点抑制剂(ICI)相关风湿性免疫相关不良事件(IRAE)的评估与治疗。风湿科医生需对接受ICI治疗并出现肌肉骨骼症状的患者进行鉴别诊断,包括炎症性关节炎、风湿性多肌痛和肌炎等。IRAE治疗按严重程度分层,证据限于观察性研究,轻度用非甾体抗炎药,中重度用糖皮质激素,部分需其他改善病情抗风湿药。
要点
- ICI相关风湿性IRAE包括炎症性关节炎、风湿性多肌痛和肌炎。
- 肌肉骨骼症状需鉴别晶体性关节炎、机械性问题及骨关节炎等。
- 肌炎可伴心肌炎或重症肌无力,需糖皮质激素并暂停ICI。
核心结论
- ICI可导致风湿性IRAE,治疗按严重程度分层,证据限于观察性研究。
- 需进一步研究优化IRAE治疗且不损害ICI抗肿瘤效果。
研究设计与样本
- 专家视角综述,总结ICI相关风湿性IRAE的评估与治疗。
主要发现
- 已报道的风湿性IRAE包括炎症性关节炎、风湿性多肌痛和肌炎。
- ICI所致肌炎可伴随心肌炎或重症肌无力。
关键数值与推荐
- 轻度炎症性关节炎和风湿性多肌痛用非甾体抗炎药治疗。
- 中重度炎症性关节炎和风湿性多肌痛用糖皮质激素,有时需其他改善病情抗风湿药。
- 肌炎通常需糖皮质激素并暂停ICI,严重者需静脉注射免疫球蛋白或血浆置换。
临床怎么用
- 对接受ICI治疗出现肌肉骨骼症状者,应鉴别IRAE与其他肌肉骨骼综合征。
- 诊断风湿性IRAE后,应与患者及肿瘤科医生共同制定治疗方案。
局限性
- IRAE管理的证据仅限于观察性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rheumatologists increasingly receive consults for patients treated with immune checkpoint inhibitors (ICIs) for cancer. ICIs can cause inflammatory syndromes known as immune-related adverse events (IRAEs). Several rheumatic IRAEs have been reported, including inflammatory arthritis, polymyalgia rheumatica, and myositis. For patients who present with musculoskeletal symptoms while receiving ICI therapy, it is important to have an algorithm for evaluation. The differential diagnosis includes a range of musculoskeletal syndromes, such as crystalline arthritis, mechanical issues, and osteoarthritis, in addition to IRAEs. After diagnosing a rheumatic IRAE, rheumatologists must work with the patient and the oncologist to form a treatment plan. Treatment of IRAEs is guided by severity. Evidence for management is limited to observational studies. Inflammatory arthritis and polymyalgia rheumatica are treated with nonsteroidal antiinflammatory drugs in mild cases, glucocorticoids for moderate-to-severe cases, and sometimes require other disease-modifying antirheumatic drugs. Myositis due to ICIs can be accompanied by myocarditis or myasthenia gravis. Glucocorticoids and withholding the ICI are usually required to treat myositis; some patients with severe myositis require intravenous immunoglobulin or plasmapheresis. Further research is needed to optimize treatment of IRAEs that does not compromise the antitumor effect of ICIs.
引用
- Cappelli LC, Bingham CO. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications. Arthritis Rheumatol. 2021. PMID: 33186490. doi:10.1002/art.41587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。